Search results
Pfizer Receives FDA Approval for Bleeding Disorder Treatment
Barrons.com· 4 days agoPfizer has received approval from the Food and Drug Administration for a rare genetic bleeding...
GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology
WSAU Wausau· 5 days agoBy Blake Brittain (Reuters) - GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on...
Pfizer Wins FDA Approval For $3.5 Million Gene Therapy
Investor's Business Daily· 4 days agoPfizer won FDA approval for a new hemophilia B gene therapy, a rival to Hemgenix from CSL and Uniqure.
FDA Green Lights Pfizer's Gene Therapy For Rare Bleeding Disorder Hemophilia - Pfizer (NYSE:PFE)
Benzinga· 4 days agoFriday, the FDA approved Pfizer Inc’s PFE Beqvez (fidanacogene elaparvovec-dzkt) for moderate to...
What Factors Will Drive Pfizer's Q1 Performance?
Forbes· 4 days agoWe expect the company to post revenue of $13.8 billion and earnings of $0.50 on a per share and adjusted basis.
US FDA approves Pfizer's gene therapy for rare bleeding disorder
Reuters· 4 days ago, opens new tab gene therapy for hemophilia B on Friday, the second such therapy for the rare...
Analysts Estimate Pfizer (PFE) to Report a Decline in Earnings: What to Look Out for
Zacks· 6 days agoFree Report) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended March 2024. This widely-known consensus outlook is important in assessing ...
Pfizer and Levi Strauss Face Challenges from Conservative Shareholders Over Support of Divisive...
National Center for Public Policy Research· 6 days agoWashington, D.C. – At this week’s Pfizer and Levi Strauss annual shareholder meetings, shareholder...
Pfizer collab with Austrian research institute leads to new AI models for drug discovery
FierceBiotech· 4 days agoA three-year collaboration between Pfizer and the Research Center for Molecular Medicine of the...
Amazon.com may be feeling pressure to join the dividend club
AOL· 1 hour agoE-commerce titan Amazon.com may be under increasing pressure to offer investors a dividend, as it now finds itself one of the few massive U.S. technology and growth companies not making regular ...